Schroder Investment Management Group Has $5.72 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Schroder Investment Management Group lowered its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 6.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 229,316 shares of the company’s stock after selling 14,537 shares during the quarter. Schroder Investment Management Group owned 0.27% of IDEAYA Biosciences worth $5,717,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. State Street Corp increased its position in IDEAYA Biosciences by 15.4% in the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company’s stock valued at $105,112,000 after acquiring an additional 443,640 shares during the period. Barclays PLC increased its holdings in IDEAYA Biosciences by 188.8% in the third quarter. Barclays PLC now owns 181,170 shares of the company’s stock valued at $5,739,000 after purchasing an additional 118,438 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in IDEAYA Biosciences by 12.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 689,073 shares of the company’s stock valued at $21,830,000 after purchasing an additional 78,518 shares during the period. Verition Fund Management LLC bought a new position in IDEAYA Biosciences during the 3rd quarter worth $246,000. Finally, Geode Capital Management LLC lifted its holdings in IDEAYA Biosciences by 9.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company’s stock worth $61,645,000 after buying an additional 172,838 shares during the period. Institutional investors own 98.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wedbush restated an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Stephens reiterated an “overweight” rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.58.

IDEAYA Biosciences Stock Down 5.5 %

Shares of IDYA opened at $14.71 on Friday. The stock has a market cap of $1.29 billion, a P/E ratio of -4.46 and a beta of 0.51. The business’s fifty day moving average is $20.05 and its 200 day moving average is $25.19. IDEAYA Biosciences, Inc. has a 12-month low of $14.40 and a 12-month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $7.00 million. On average, analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.